Baloxavir safety and clinical and virologic outcomes in influenza virus-infected pediatric patients by age group: age-based pooled analysis of two pediatric studies conducted in Japan

Table 3 Recurrence of influenza symptoms and fever by age group and influenza virus type (subtype)

Influenza virus type (subtype) Variable	< 6 years % (*n/N*)	≥6 to < 12 years % (*n/N*)
A(H1N1)pdm09
Symptom recurrence after day 4^a	16.7 (1/6)	0.0 (0/1)
Fever recurrence after day 4^b	11.1 (1/9)	25.0 (1/4)
A(H3N2)
Symptom recurrence after day 4^a	21.1 (4/19)	25.6 (11/43)
Fever recurrence after day 4^b	29.6 (8/27)	5.9 (4/68)
B
Symptom recurrence after day 4^a	54.5 (6/11)	0.0 (0/3)
Fever recurrence after day 4^b	50.0 (8/16)	25.0 (1/4)

Patients in the ITTI population with a single influenza virus type (subtype) infection were included in the analysis
ITTI intention-to-treat infected
^aThe symptom score (cough and nasal discharge/nasal congestion) was assessed as moderate or severe at least once after day 4 and the score increase was observed compared with the previous time point. The subset of patients with confirmed alleviation of influenza illness before day 4 was included in this analysis. Alleviation of symptoms was defined as when the following criteria were met and sustained for ≥21.5 hours: cough and nasal discharge/nasal congestion both assessed as absent or mild, and axillary temperature < 37.5 °C
^b37.5 °C or more in body temperature was observed after day 4 and body temperature was increased compared with the previous time point. The subset of patients with confirmed resolution of fever before day 4 was included in this analysis. Resolution of fever was defined as an axillary temperature < 37.5 °C and sustained for ≥12 hours